Publications by Julieann Sludden - ePrints

Browsing publications by Julieann Sludden.

Newcastle Authors	Title	Year
Julieann Sludden Professor Gareth Veal Professor Ruth Plummer	A Phase 1/2A trial of idroxioleic acid: First-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma	2023
Dr Shelby Barnett Julie Errington Julieann Sludden Dr David Jamieson Professor Gareth Veal et al.	Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population	2021
Monique Zangarini Philip Berry Julieann Sludden Professor Gareth Veal	Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma	2017
Dr David Jamieson Dr Nicola Sunter Sara Muro Dr Nicola Cresti Julieann Sludden et al.	Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide	2017
Dr David Jamieson Melanie Griffin Julieann Sludden Dr Yvette Drew Dr Nicola Cresti et al.	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours	2016
Professor Gareth Veal Julieann Sludden Dr David Jamieson Julie Errington Dr Ghada Malik et al.	Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma	2016
Dr Yvette Drew Dr Martin Highley Julieann Sludden Dr James Murray Dr David Jamieson et al.	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer	2016
Dr James Murray Julieann Sludden Professor Alan Boddy Professor Nicola Curtin	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System	2015
Dr David Jamieson Dr Jo Lee Dr Nicola Cresti Melanie Griffin Julieann Sludden et al.	Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil	2014
Professor Ruth Plummer Professor Alan Boddy Julieann Sludden	A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours	2011
Dr David Jamieson Dr Nicola Cresti Julieann Sludden Melanie Griffin Nahed Hawsawi et al.	Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy	2011
Julieann Sludden Melanie Griffin Mike Cole Dr Mark Verrill Dr David Jamieson et al.	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide	2010
Professor Ruth Plummer Melanie Griffin Dr Sally Coulthard Julieann Sludden Professor Alan Calvert et al.	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors	2009
Dr Jo Lee Dr Mark Verrill Julieann Sludden Melanie Griffin Sharon Erb et al.	Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer	2007
Professor Alan Boddy Julieann Sludden Melanie Griffin Professor Herbie Newell Professor Stephen O'Brien et al.	Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia	2007
Dr Jo Lee Julieann Sludden Professor Alan Boddy Dr Mark Verrill	Investigation of multi-drug resistance 1 (MDR1) and cytochrome P4502C8 (CYP2C8) pharmacogenetics on outcome from treatment of advanced breast cancer using paclitaxel in a UK national trial of a weekly versus 3-weekly schedule.	2006
Mark Leslie Julieann Sludden Professor Ruth Plummer Professor Alastair Greystoke Professor Alan Calvert et al.	A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.	2005
Professor Alan Boddy Professor Ruth Plummer Julieann Sludden Melanie Griffin Dr Mark Verrill et al.	A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules	2005
Professor Gareth Veal Julie Errington Julieann Sludden Melanie Griffin Annie Parry et al.	Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry	2003
Julie Errington Professor Gareth Veal Julieann Sludden Melanie Griffin Professor Andrew Pearson et al.	Determination of the anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry	2003
Dr Mark Verrill Professor Alan Boddy Julieann Sludden Kevin Fishwick Lynsey Robson et al.	Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors	2003
Professor Alan Boddy Dr Mark Verrill Julieann Sludden Kevin Fishwick Lynsey Robson et al.	Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study	2002
Dr Andrew Simpson Dr Paula Calvert Julieann Sludden Professor Alan Boddy Melanie Griffin et al.	Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules	2002
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer	2001
Professor Alan Boddy Dr Mark Verrill Julieann Sludden Melanie Griffin Kevin Fishwick et al.	Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate	2001
Julieann Sludden	Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations	2000
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer	2000
Dr Gordon Strathdee Julieann Sludden	Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter	2000
Julieann Sludden	The encapsulation of bleomycin within chitosan based polymeric vesicles does not alter its biodistribution	2000
Julieann Sludden	Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II	1999
Julieann Sludden	Phase I/ Pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion	1999
Julieann Sludden	The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations	1999
Julieann Sludden	Autoregulation of 5-fluorouracil metabolism	1998
Julieann Sludden	Characterisation of dihydropyrimidine dehydrogenase in human colorectal tumours	1998
Julieann Sludden	Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects	1998
Julieann Sludden	Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer	1998
Julieann Sludden	Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals	1998
Julieann Sludden	Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey , dog, rat and mouse	1998
Julieann Sludden	Polymeric chitosan-based vesicles for drug delivery	1998